Merck Acquires Late-Stage Congestive Heart Failure Drug With $350 Million NovaCardia Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III program for KW-3092 will continue as laid out by NovaCardia, Merck exec tells “The Pink Sheet” DAILY.